Taeang Arai

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Andrea Casadei‐Gardini, Margherita Rimini, Toshifumi Tada et al. · European Journal of Cancer · 2022 · 129 citations · Full text

Medicine, Oncology, Pharmacology +15

Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease

Erina Kumagai, Yohei Mano, Sachiyo Yoshio et al. · Scientific Reports · 2016 · 105 citations · Full text

Medicine, Pathobiology, Pathology +17

Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib

Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka et al. · Liver International · 2020 · 97 citations · Full text

Medicine, Oncology, Pharmacology +11

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience

Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada et al. · Cancer Reports · 2021 · 80 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study

Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka et al. · Hepatology International · 2022 · 80 citations

Medicine, Oncology, Pharmacotherapy +17